Logo

F2G Receives the US FDA's Breakthrough Therapy Designation for Olorofim

Share this

F2G Receives the US FDA's Breakthrough Therapy Designation for Olorofim

Shots:

  • The US FDA has granted BTD to Olorofim for the treatment of CNS Valley Fever (coccidioidomycosis)
  • The therapy is currently being evaluated in P-IIb study in patients with coccidioidomycosis with proven IFD or probable IA and either refractory disease- resistance- or intolerance to available agents
  • The BTD follows the previous BTD that was granted on Nov 11- 2019- for the treatment of invasive mold infections in patients with limited or no treatment options- including aspergillosis refractory or intolerant to currently available therapy- and infections due to Lomentospora prolificans- Scedosporium- and Scopulariopsis species

 ­ Ref: PRNewswire | Image: F2G

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions